FDA outlines regulatory path for drisaperson

The FDA clarifies an accelerated approval pathway for Prosensa Holdings' (RNA) Duchenne Muscular Dystrophy drug drisapersen based on existing data. The company plans to file its NDA later this year and commits to two confirmatory post-approval studies.

Prosensa will follow through on its plan to re-dose an initial cohort of boys in Q3 who have previously participated in drisapersen clinical studies.

Shares are up 13% premarket on fair volume.

Also benefiting from the good news is Sarepta Therapeutics' (SRPT) eteplirsen. The company also plans to file its NDA by year end.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs